Shares of BioTime, Inc. (NYSEAMERICAN:BTX) traded up 9.2% during mid-day trading on Monday . The stock traded as high as $2.80 and last traded at $2.74. 1,118,676 shares traded hands during trading, an increase of 63% from the average session volume of 686,655 shares. The stock had previously closed at $2.51.

Several analysts have issued reports on the company. BidaskClub raised BioTime from a “sell” rating to a “hold” rating in a report on Thursday, September 28th. Zacks Investment Research lowered BioTime from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $5.08.

The stock has a market cap of $318.43, a price-to-earnings ratio of 6.30 and a beta of 2.03.

In other BioTime news, Director Broadwood Partners, L.P. acquired 2,692,307 shares of the stock in a transaction dated Friday, October 13th. The shares were acquired at an average cost of $2.60 per share, for a total transaction of $6,999,998.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of BioTime by 17.0% in the second quarter. Vanguard Group Inc. now owns 3,680,705 shares of the biotechnology company’s stock worth $11,594,000 after buying an additional 534,527 shares in the last quarter. Broadwood Capital Inc. lifted its position in shares of BioTime by 0.6% in the third quarter. Broadwood Capital Inc. now owns 27,279,254 shares of the biotechnology company’s stock worth $77,473,000 after buying an additional 160,000 shares in the last quarter. State Street Corp lifted its position in shares of BioTime by 10.3% in the second quarter. State Street Corp now owns 1,345,379 shares of the biotechnology company’s stock worth $4,238,000 after buying an additional 125,833 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of BioTime in the second quarter worth about $380,000. Finally, IndexIQ Advisors LLC lifted its position in shares of BioTime by 83.1% in the third quarter. IndexIQ Advisors LLC now owns 251,227 shares of the biotechnology company’s stock worth $713,000 after buying an additional 114,003 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/biotime-btx-trading-9-2-higher/1801302.html.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with Analyst Ratings Network's FREE daily email newsletter.